Company profile

Future of Bayer

#
Rank
69
| Quantumrun Global 1000

Bayer AG is a German life science, pharmaceutical, and chemical company that operates globally. Headquartered in Leverkusen, where its sign illuminates brightly is a landmark. Bayer's main areas of business include high-value polymers, consumer healthcare products, human and veterinary pharmaceuticals, agricultural chemicals and biotechnology products.

Home Country:
Sector:
Industry:
Pharmaceuticals
Website:
Founded:
1863
Global employee count:
115170
Domestic employee count:
30000
Number of domestic locations:
20

Financial Health

Revenue:
$46769000000 EUR
3y average revenue:
$44731000000 EUR
Operating expenses:
$19432000000 EUR
3y average expenses:
$18090333333 EUR
Funds in reserve:
$1899000000 EUR
Revenue from country
0.34
Revenue from country
0.28
Revenue from country
0.22

Asset Performance

  1. Product/Service/Dept. name
    Pharmaceuticals
    Product/Service revenue
    3986000000
  2. Product/Service/Dept. name
    Consumer health
    Product/Service revenue
    1506000000
  3. Product/Service/Dept. name
    Crop science
    Product/Service revenue
    2405000000

Innovation assets and Pipeline

Global brand rank:
336
Investment into R&D:
$4666000000
Total patents held:
12680

All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page. 

DISRUPTION VULNERABILITY

Belonging to the healthcare and agricultural sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.
*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.
*Artificial intelligence (AI) systems will discover new thousands of new compounds faster than humans that can, compounds that can be applied to everything from creating new makeup to cleaning agents to more effective medicines.
*This automated process of chemical compound discovery will accelerate once AI systems are integrated with mature quantum computers by the late 2020s, allowing these AI systems will compute ever more massive amounts of data.

*Meanwhile, as it relates to its agriculture division, Bayer will become susceptible to the following additional trends:
*By 2050, the world’s population will balloon far past nine billion people; feeding that many people will keep the food and beverage industry growing into the foreseeable future. However, providing the food necessary to feed that many people is beyond the world’s current capacity, especially if all nine billion demand a Western-style diet.
*Meanwhile, climate change will continue to push global temperatures upward, eventually far beyond the optimal growing temperatures/climate of the world’s staple plants, like wheat and rice—a scenario that can endanger the food security of billions.
*As a result of the two factors above, this sector will collaborate with the top names in agribusiness to create new agri-chemicals and novel GMO plants and animals that grow faster, are climate resistant, are more nutritious, and can ultimately produce far greater yields.
*The early 2030s will also see food substitutes/alternatives become a booming industry. This will include a larger and cheaper range plant-based meat substitutes, algae-based food, soylent-type, drinkable meal replacements, and high protein, insect-based foods.

COMPANY’S FUTURE PROSPECTS

Company Headlines